immunogenic cell death and cyclophilin signaling pathways were significantly higher, while the RhoGDI, PPAR and inhibition of matrix metalloproteases (MMPs) signaling pathways were lower in PDLIM2-low lung fibroblasts of COVID-19 patients (Fig. 9B–9F). This evidence concerns the gene PDLIM2 and COVID-19.